Diabetes

INDIANAPOLIS — Many people with Type 2 diabetes have managed to integrate the treatments they must take into their daily lives, but many do not reach their blood-glucose goals after they start insulin therapy.

Drug maker Eli Lilly is partnering with Brigham and Women's Hospital in Boston in a study that started in July and has enrolled 4,500 people in 17 countries to find out why many people with the disease resist a progression of insulin therapy.

SILVER SPRING, Md. — In an effort to help advance the development of devices that automatically monitor blood glucose and provide proper insulin doses in people with Type 1 diabetes, the Food and Drug Administration has issued draft guidance to help investigators and manufacturers as they develop and seek approval for these products.

TUSTIN, Calif. — A new meta-analysis released Wednesday of eight clinical trials examining the effect of cinnamon consumption in people with Type 2 diabetes and/or prediabetes concluded cinnamon extract and/or cinnamon helps lower blood-glucose levels. The analysis was published in the Journal of Medicinal Foods.

NEW YORK — Record-breaking attendance, a high-profile keynote speaker, four engaging panel discussions on some of the hottest issues facing the industry and exclusive consumer videos set the stage for the 13th annual Drug Store News Industry Issues Summit held on Tuesday in New York.

EAST LANSING, Mich. — A drug commonly used to treat Type 2 diabetes may reduce the risk of diabetes-associated cancers, including breast cancer, according to a new study.

OSAKA, Japan — A U.S. subsidiary of Takeda Pharmaceutical has filed for regulatory approval of a drug designed to treat Type 2 diabetes, the company said.

The Takeda Global Research and Development Center filed with the Food and Drug Administration for approval of an alogliptin-metformin combination tablet. The company expects the FDA to review the application within the next 10 months.

ATLANTA — Many elderly patients put themselves at risk for emergency hospitalization due to adverse drug events, according to a new Centers for Disease Control and Prevention study published in the New England Journal of Medicine.

NEW YORK — A test commonly used to identify patients with diabetes or those at risk of developing the condition may not produce accurate results among children, according to a new study conducted by researchers at the University of Michigan.

The study, published online ahead of print in the journal Diabetes Care, tested 254 overweight children using both fasting and nonfasting methods. Researchers found that the recommended test, hemoglobin A1C (HbA1C), missed more cases of prediabetes or diabetes, compared with other tests.